Related Experiment Videos
[LDL-apheresis: current status].
C Stefanutti1, A Vivenzio, G Lucani
1Sezione di Plasmaferesi Terapeutica, Istituto di Terapia Medica Sistematica, Policlinico Umberto I, Università degli Studi di Roma La Sapienza, Roma, Italia. plasmaferesi@tin.it
La Clinica Terapeutica
|May 31, 2001
Summary
LDL-apheresis effectively treats severe familial hypercholesterolemia in pediatric and adult patients. This advanced therapy improves metabolic function and prevents atherosclerotic complications, offering a safe and effective treatment option.
Area of Science:
- Cardiovascular Medicine
- Metabolic Disorders
- Medical Technology
Context:
- Familial hypercholesterolemia (FH) is a severe genetic disorder leading to premature cardiovascular disease.
- Current treatment strategies for severe FH, particularly in pediatric populations, require effective and safe interventions.
- LDL-apheresis represents a significant therapeutic advancement for managing extreme lipid profiles.
Purpose:
- To review the current state of LDL-apheresis for treating severe familial hypercholesterolemia.
- To present clinical experience with LDL-apheresis in pediatric and adult FH patients.
- To evaluate the efficacy and safety of various LDL-apheresis techniques (DALI, HELP, DSC).
Summary:
- LDL-apheresis was applied to 11 pediatric patients, including a 3.5-year-old, demonstrating its applicability in very young individuals.
- The treatment successfully improved metabolic abnormalities associated with FH.
- LDL-apheresis effectively halted the progression of atherosclerotic disease and its complications in treated patients.
Impact:
- LDL-apheresis is established as a highly effective and safe therapeutic approach for homozygous, heterozygous, and double heterozygous FH.
- Early intervention with LDL-apheresis in pediatric patients can significantly alter the long-term prognosis of FH.
- This therapy provides a critical treatment option for patients with severe hypercholesterolemia unresponsive to conventional management.